Preview

May 2020

In the next issue of Pharma Technology Focus, we take a look back at mumps treatments in England following reports that the number of cases in the country is set to reach heights not seen in a decade, find out what happened to the whistleblowers that spread early warnings during past epidemics, and speak to CPP development company Peptomyc about its approach to cancer treatment.

Plus, we explore ways that pharma can be reformed to help tackle the threat of climate change-related health issues, investigate the safety of inactive pharma ingredients, and ask if spin-out companies are set to become a more regular feature in pharma.

Also, we find out about a topical gene therapy that waves goodbye to needles, and take a look at a drug development playbook compiled by data analytics platform Signals Analytics.

EDITORIAL

Editor | Eloise McLennan

Group Editor | Susanne Hauner

Commissioning Editor| Daniel Garrun

Writers | Allie Nawrat, Chloe Kent 
Magazine Designer | Marzia Del Gaone

Graphic Designers | Filipe Costa, Anett Arc, Ashley McPherson, Tyrrell Lowe, Noemi Balint, Petra Konyi-Kiss, Maria Gimenez, Martina Labaiova
Lead Designer | John Hammond 
Digital Publishing Director | Duncan West

Advertising

Sales Manager | Nimai Amin

+44 (0) 207 936 6453

Marketing

For media partnership enquiries please contact our publishing assistant: Sophie Hoare

Pharma Technology focus is powered by h5mag

read past issues of pharma technology focus HERE

Copyright 2020 NRi Digital, a trading division of Verdict Media Ltd. Registered office John Carpenter House, John Carpenter Street, London, EC4Y 0AN, UK. Company registration number 03171601. All rights reserved. No part of this publication may be reproduced in any form or by any means, electronic, photocopying or otherwise, without prior permission of the publisher and copyright owner. While every effort has been made to ensure the accuracy of this publication, the publisher accepts no responsibility for errors or omissions. The products and services advertised are those of individual authors and are not necessarily endorsed by or connected with the publisher. The opinions expressed in the articles within this publication are those of individual authors and not necessarily those of the publisher.

Go to article: Home | US excess vs. global accessGo to article: EditorialGo to article: VEGA Company Insight Go to article: VEGA AustraliaGo to article: ContentsGo to article: ELPRO Monitoring SolutionsGo to article: NewsGo to article: BaxterGo to article: The pharma industry briefingGo to article: Datwyler Company Insight Go to article: DatwylerGo to article: Turning pharma green: an eco-wish list for the industryGo to article: Scandinavian Health Company InsightGo to article: Scandinavian HealthGo to article: Q&A: disrupting DNA synthesis with Twist’s Emily LeproustGo to article: Phoenix Company InsightGo to article: PhoenixGo to article: Tips and tricks for regulating advanced therapiesGo to article: Gerteis Company InsightGo to article: GerteisGo to article: Lyme disease: what's actually going on here?Go to article: Subcuject Company Insight Go to article: SubcujectGo to article: The US and the developing world: a tale of two opioid crises Go to article: KugelmeiersGo to article: Tracking priority medicines in transit: UPS launches tech-enabled serviceGo to article: Modality SolutionsGo to article: When deadlines turn deadly: examining the psychology of drug regulatorsGo to article: Zenatek Go to article: Proteus Digital Health: a sharp lesson for smart pills?Go to article: MimotopesGo to article: Deals in brief powered by GlobalDataGo to article: MicronovaGo to article: The key list powered by GlobalDataGo to article: EmisphereGo to article: Markets and Indices powered by GlobalDataGo to article: Macro-economic indicators (1 of 2) powered by GlobalDataGo to article: Macro-economic indicators (2 of 2) powered by GlobalDataGo to article: Air FranceGo to article: EventsGo to article: ILC Dover Go to article: Next issue